Finance

Lists
TRUMY:OTCMKTS
Terumo ADR
14,65 US$
+0,96%
(+0,14) 1D
16 ოქტ, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TRUMY...
Open
14,57 US$
High
14,74 US$
Low
14,57 US$
Mkt. cap
3,45 ტრლ.
Avg. vol.
115,96 ათ.
Volume
94,09 ათ.
52-wk high
17,81 US$
52-wk low
12,08 US$
Beta
0,77
Shares outstanding
1,48 მლრდ.
No. of employees
31 ათ.
Open
14,57 US$
High
14,74 US$
Low
14,57 US$
Mkt. cap
3,45 ტრლ.
Avg. vol.
115,96 ათ.
Volume
94,09 ათ.
52-wk high
17,81 US$
52-wk low
12,08 US$
Beta
0,77
Shares outstanding
1,48 მლრდ.
No. of employees
31 ათ.
News stories
From web sources and news partners
ad-hoc-news.de
ad-hoc-news.de
·
1 დღის წინ
Jefferies keeps JPY 2,700 target for Terumo stock
Profile
Terumo Corporation was founded in 1921 as Red Line Thermometer Corporation by a group of medical scientists led by Dr. Kitasato Shibasaburō to produce medical thermometers in Japan. The company's first product was "Jintan Taionkei", the first Japanese-made thermometer available for sale, and it has since expanded into a medical devices manufacturer, producing medical disposables, cardiovascular systems and diabetes care products. In 1971, Terumo opened its first overseas office in the United States. Since then, the company has established subsidiaries in Europe, South America, China, India, Philippines, Vietnam, Thailand, Australia and México. The company later expanded its product range to include coronary stents and catheters, and acquired, among others, the cardiovascular specialty companies Vascutek and Microvention in 2002 and 2006 respectively. Wikipedia
About Terumo ADR
CEO-
Employees31,2 ათ.
Founded17 სექ. 1921
Headquartersშიბუია, ტოკიო, იაპონია
SectorMedical device
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
274,96 მლრ.
296,63 მლრ.
300,32 მლრ.
311,81 მლრ.
Cost of goods sold
127,97 მლრ.
143,44 მლრ.
149,06 მლრ.
133,27 მლრ.
Cost of revenue
127,97 მლრ.
143,44 მლრ.
149,06 მლრ.
133,27 მლრ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
97,88 მლრდ.
105,26 მლრ.
107,66 მლრ.
109,70 მლრ.
Operating expense
101,90 მლრ.
109,31 მლრ.
98,62 მლრდ.
89,06 მლრდ.
Total operating expenses
229,87 მლრ.
252,74 მლრ.
247,68 მლრ.
222,33 მლრ.
Operating income
45,10 მლრდ.
43,88 მლრდ.
52,64 მლრდ.
89,48 მლრდ.
Other non operating income
-1,00 მლნ.
2,00 მლნ.
-409,00 მლნ.
-4,00 მლნ.
EBT including unusual items
45,95 მლრდ.
45,38 მლრდ.
31,66 მლრდ.
90,32 მლრდ.
EBT excluding unusual items
45,95 მლრდ.
45,38 მლრდ.
52,86 მლრდ.
90,32 მლრდ.
Income tax expense
10,90 მლრდ.
12,72 მლრდ.
5,30 მლრდ.
19,89 მლრდ.
Effective tax rate
23,72%
28,04%
16,73%
22,03%
Other operating expenses
4,02 მლრდ.
4,05 მლრდ.
-9,05 მლრდ.
-20,64 მლრდ.
Net income
35,05 მლრდ.
32,65 მლრდ.
26,37 მლრდ.
70,43 მლრდ.
Net profit margin
12,75%
11,01%
8,78%
22,59%
Earnings per share
-
-
-
-
Interest and investment income
1,02 მლრდ.
2,21 მლრდ.
-
2,38 მლრდ.
Interest expense
-18,00 მლნ.
-463,00 მლნ.
-1,32 მლრდ.
-1,48 მლრდ.
Net interest expenses
1,00 მლრდ.
1,75 მლრდ.
-1,32 მლრდ.
905,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
66,76 მლრდ.
69,98 მლრდ.
79,07 მლრდ.
116,67 მლრ.
Gain or loss from assets sale
4,72 მლრდ.
154,00 მლნ.
188,00 მლნ.
12,00 მლნ.
AI content may include mistakes. Learn more
Google აპები